UK industry code of practice to be reviewed
January 7, 2005Sales and Marketing
The ABPI has announced a major review of its self-regulated Code of Practice, seeking the views of stakeholders on the …
Industry contributes to disaster relief in Asia
January 6, 2005Sales and Marketing AZ, GSK, WHO, disaster, relief, tsunami
Pharmaceutical companies have joined worldwide efforts to bring relief to areas devastated by the tsunami in Asia, donating money and …
Community matrons to manage chronic disease
January 5, 2005A new role of community matron is to be created to help millions of people with long-term conditions improve their …
The weight of evidence – the stories that changed pharma in 2004
January 4, 2005Research and Development 2004, Vioxx, year in review
Ticking time bombsIn 2004, countries around the world faced up to some home truths about the health of their populations …
Zocor and the high street revolution
January 4, 2005Sales and Marketing
It’s an exciting time for consumer healthcare divisions in the pharma industry. Two years ago, the Department of Health (DH) …
Advert exaggerated Plavix benefits
January 4, 2005Medical Communications
An advert for anti-clotting drug Plavix has been found in breach of advertising rules because of exaggerated claims of efficacy …
Yamanouchi to launch prostate cancer drug Eligard
December 30, 2004Sales and Marketing
A new treatment for advanced prostate cancer, Eligard, has received approval in 24 European countries and will be marketed by …
Avandia advert hypertension claims ‘misleading’
December 30, 2004Sales and Marketing
Claims that GlaxoSmithKline's diabetes drugs Avandia and Avandamet help to significantly lower blood pressure broke the UK Code of advertising, …
Personalised medicine moves a step closer
December 30, 2004Research and Development, Sales and Marketing
Doctors will be able to use genetic information to determine the best drug dosage for individual patients following approval of …
Trial data sounds death knell for Iressa
December 21, 2004Sales and Marketing
AstraZeneca has effectively given up on its cancer drug Iressa, admitting that data from a new large scale trial shows …
FDA recommends alternatives following Celebrex scare
December 21, 2004Sales and Marketing
A new study linking Celebrex to the same increased risk of heart attacks and strokes as recently withdrawn Vioxx has …
AstraZeneca looks to Iressa successor after setback
December 16, 2004Research and Development
AstraZeneca says it is optimistic about two of its most advanced cancer pipeline drugs, which it hopes will offset a …
Restructured Takeda to go it alone on hypertension drug
December 16, 2004Takeda is to assume full control of marketing hypertension drug candesartan in the UK from January, ending a seven-year collaboration …
Payments by Results could bankrupt hospitals, say doctors’ leaders
December 16, 2004NHS hospitals that fail to attract patients could become bankrupt under the Payments by Results system, doctors' leaders have warned.Due …
Academics raise alarm over trial costs
December 15, 2004Leading UK academic researchers say extra costs and bureaucracy from new European laws are killing off their work, and have …
Taking the plunge
December 10, 2004When prompted to do some forward thinking, I often start by looking back. In 1999 I was an evangelist for …
Latest content
FibroFind appoints Lee Borthwick as CEO
